The Latest Recommendations for Incyte

Analysts’ estimates

Wall Street analysts expect Incyte (INCY) to report a 17.8% YoY (year-over-year) rise in sales to $1.81 billion in 2018 compared to $1.54 billion in 2017.

Incyte is expected to report net adjusted income of $245.1 million in 2018 compared to net adjusted income of -$313.1 million in 2017. Its EPS are expected to be $1.11 in 2018. The growth in its revenue in 2018 is expected to be driven by strong sales of Jakafi and Iclusig.

The Latest Recommendations for Incyte

The chart above compares changes in analysts’ recommendations for Incyte stock over the last 12 months.

Analysts’ recommendations

Incyte’s stock price has fallen nearly 42.4% over the last 12 months and nearly 26.5% year-to-date in 2018. Analysts expect the stock to rise ~21.9% over the next 12 months. Their recommendations show a 12-month target price of $84.85 per share compared to the stock’s price of $69.62 per share on August 21.

As of August 21, 18 analysts are tracking Incyte stock. Of these 18 analysts, two have recommended “strong buys,” 11 have recommended “buys,” and five have recommended “holds,” while none have recommended “sells” on the stock. The consensus rating for Incyte stands at 2.17, which represents a “buy” for momentum investors as well as long-term investors. Changes in analysts’ recommendations and estimates for a company’s target price are based on the changes in the trends in its stock price as well as developments and changes in its performance.

The iShares Evolved US Innovative Healthcare ETF (IEIH) holds 0.5% of its total investments in Incyte, 4.9% in Biogen (BIIB), 7.0% in Pfizer (PFE), and 4.4% in Gilead Sciences (GILD).